Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study.

Background: Conjunctivitis is among the most frequent adverse events (AEs) emerged in clinical trials for all biologic drugs approved for atopic dermatitis (AD). However, real-world comparative data on the incidence, risk factors, and management of conjunctivitis remain limited.

Objective: We aimed to compare the incidence, clinical features, and management of conjunctivitis in patients with moderate-to-severe AD treated with dupilumab or tralokinumab in a real-life setting.

Effectiveness of Tralokinumab for Moderate-to-Severe Atopic Dermatitis Involving the Head-and-Neck Area: A Multicenter Retrospective Cohort Study.

Atopic dermatitis (AD) affecting the head and neck (H&N) area poses a clinical challenge due to the unique anatomical and physiological features of this region. Despite its well-documented impact on quality of life (QoL), evidence on the effectiveness of tralokinumab in treating AD specifically in the H&N area remains limited. To assess the clinical outcomes of tralokinumab in AD patients with H&N involvement, informing clinical decision-making and improving patient care.

Clinical Course of Atopic Dermatitis after Dupilumab Discontinuation: A Multicenter Real-World Study.

Introduction: Limited data exist on the clinical course of atopic dermatitis (AD) after the discontinuation of dupilumab. This study aims to assess disease progression following dupilumab discontinuation.

Methods: A multicenter, retrospective study was conducted on 208 patients with severe AD who discontinued dupilumab for reasons unrelated to inefficacy.

Journey of Patients with Psoriasis in an Italian Tertiary Centre, an 11-year Retrospective Analysis.

Despite the improvement of psoriasis treatment achieved with the use of biological therapies, some patients still require hospitalization. A retrospective study was conducted including patients affected by psoriasis hospitalized at Fondazione Policlinico Agostino Gemelli IRCCS in Rome, from 1 January 2012 to 1 August 2023, to describe the psoriasis patient journey. Of the 2.

Histological features of immune cell infiltrate in lesional skin correlate with therapeutic response to dupilumab.

Over the past decade, dupilumab, a monoclonal human antibody that inhibits interleukin (IL)-4 and IL-13 signalling, has revolutionized the therapeutic management of moderate-to-severe atopic dermatitis (AD), facilitating long-term control of its signs and symptoms. The aim of this study was to identify histological predictors of the efficacy of dupilumab after 16 weeks of treatment in a cohort of 40 adults with moderate-to-severe AD who had undergone a skin biopsy for diagnostic purposes before treatment initiation. We found that Eczema Area and Severity Index (EASI) 75 and EASI 90 responses at week 16 were significantly associated with perivascular localization [odds ratio (OR) 17.

Low grade of satisfaction related to the use of current systemic therapies among pustular psoriasis patients: a therapeutic unmet need to be fulfilled.

Introduction: Pustular psoriasis is considered a separate entity from plaque psoriasis and can be categorized as generalized pustular psoriasis (GPP), acrodermatitis continua of Hallopeau, or palmoplantar pustulosis (PPP). Current guidelines mostly include treatment options that have not been specifically developed for the treatment of pustular psoriasis. The majority of them does not have indication for the treatment of pustular psoriasis.

Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study.

Background: Tuberculosis has a major global impact. Immunocompetent hosts usually control this disease, resulting in an asymptomatic latent tuberculosis infection (LTBI). Because TNF inhibitors increase the risk of tuberculosis reactivation, current guidelines recommend tuberculosis screening before starting any biologic drug, and chemoprophylaxis if LTBI is diagnosed.

Clinical Features and Response to Treatment in Elderly Subjects Affected by Hidradenitis Suppurativa: A Cohort Study.

Hidradenitis suppurativa (HS) is a chronic-relapsing inflammatory skin disease. It usually appears in the second and third decades, but a smaller proportion of patients develop late-onset HS. Geriatric HS, defined as the persistence or the development of HS after the age of 65 years, has been poorly explored.